Acquisition Opportunity Jubilee Clinical Research was acquired by Pinnacle Clinical Research (via LongueVue Capital) in September 2024, indicating a shift in ownership and potential operational integration. This presents an opening to approach Pinnacle and its portfolio for cross-sell of services, capacity planning, and standardized study startup efficiencies.

Midmarket Scale With a small team of 2-10 employees and revenue in the $1M-$10M range, JCR represents a lower-volume, boutique site with flexibility and potential for strategic partnerships, site optimization, and high-touch sponsor engagement to maximize per-study revenue and repeat contracts.

Diversified Indications JCR actively enrolls in a wide range of indications from antibiotics to diabetic therapeutics and beyond, suggesting opportunities to pitch a broad portfolio of study types, including complex trials, multi-therapeutic programs, and late-phase collaboration.

Strategic Partnerships The collaboration with Operation H.O.P.E. signals a mission-driven approach and potential for philanthropic or socially responsible funding angles, which can be attractive to sponsors prioritizing ESG and patient access programs in studies.

Tech and Security Stack JCR leverages cloud and security tools (Google Cloud CDN, Google Cloud, Sentry, HSTS) and has a Wix-based web/eCommerce footprint, indicating a digital-forward site capable of sponsor dashboards, remote monitoring, and modern eClinical operations, suggesting readiness for tech-enabled trials and virtual site management.